Torrent Pharmaceuticals has announced that Ameera Shah has ceased to be an Independent Director of the company on August 1, 2026. The change in board composition occurs following the completion of her term, marking a routine transition in the company’s governance structure rather than a voluntary resignation or removal. This development ensures the board maintains its required independence ratios as per regulatory norms, with the company expected to initiate the process for appointing a successor in due course.

The intimation was filed with the Bombay Stock Exchange and the National Stock Exchange on August 1, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, which mandates timely reporting of changes in directorship. Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals, signed the communication, confirming the cessation effective from the specified date.

Key Details of Cessation

The filing explicitly states that the reason for the change is the "completion of term," distinguishing this event from resignation, removal, or other forms of departure. Ameera Shah’s tenure ended on August 1, 2026, after which she ceased to hold any directorial position within the company. The disclosure includes her Director Identification Number (DIN) 00208095 for regulatory tracking purposes.

Governance Implications

The departure of an Independent Director triggers specific procedural requirements under the Companies Act, 2013, and SEBI listing regulations. Torrent Pharmaceuticals must now ensure that the board continues to meet the minimum requirement for independent directors, which is typically one-third of the total board strength for listed entities. While the filing does not mention an immediate successor, companies usually announce nominations or open applications for such roles in subsequent board meetings or through postal ballots.

This transition is part of the normal lifecycle of board appointments, where independent directors serve fixed terms subject to reappointment by shareholders. The company’s registered office remains at Avirat, Thaltej Shilaj Road, Ahmedabad, and investor communications continue through its designated email address, investorservices@torrentpharma.com . No financial impact or operational disruption is associated with this governance change.

Torrent Pharmaceuticals reported a consolidated net profit of ₹566 crore for the quarter ended June 30, 2026, marking a 3% increase from ₹548 crore in the same period last year. Consolidated revenue from operations surged 55% year-on-year to ₹4,921 crore, significantly boosted by the inclusion of J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) following its amalgamation with effect from January 21, 2026. The company's operational EBITDA rose 61% to ₹1,664 crore, with a margin of 33.81% compared to 32.47% in the year-ago period. The Board of Directors approved the unaudited standalone and consolidated financial results on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The statutory auditors, B S R & Co. LLP, issued a limited review report on the financial statements pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations. The audit concluded that nothing came to their attention to cause them to believe that the statement had not disclosed all required information or contained any material misstatement. The comparative figures for the quarter and year ended March 31, 2026, have been restated to reflect the pooling of interest method accounting for the JB Pharma merger, as approved by the National Company Law Tribunal (NCLT) on July 6, 2026.

Financial Performance Breakdown

The consolidated revenue surge was underpinned by robust performance across both the base business and the newly integrated JB Pharma segment. The base business generated revenues of ₹3,720 crore, representing a 17% organic growth year-on-year. The JB Pharma segment contributed ₹1,201 crore, up 10% compared to the prior year's corresponding period. Standalone revenue reached ₹4,158 crore, up from ₹2,616 crore in Q1FY26, with standalone net profit standing at ₹492 crore.

The table below summarises the key consolidated financial metrics for the quarter:

*Before exceptional items

Exceptional items impacted the bottom line by ₹21 crore in Q1FY27. This included ₹2 crore towards regulatory and statutory fees associated with the JB Pharma acquisition, and a ₹19 crore inventory write-off due to a fire incident at an erstwhile JB Pharma warehouse. The company noted that no effect has been given to the related insurance claim, which remains under assessment. Additionally, severance compensation of ₹19 crore was recorded in the previous fiscal year related to the restructuring of JB Pharma's distribution network.

Regional Business Highlights

The India business delivered record high organic growth, with revenues reaching ₹2,157 crore, up 19% year-on-year against an IPM market growth of 12%. Torrent secured the top rank in the Indian cardiac market and saw its generic Semaglutide product achieve a 36% market share in Q1FY27. Internationally, US revenues grew 36% to ₹418 crore, driven by new launches. Brazil revenues increased 27% to ₹277 crore, although the company undertook a one-time channel inventory reduction due to credit period requests amid rising interest costs. Germany revenues remained flat at ₹318 crore, impacted by supply disruptions.

What the Numbers Show

The significant divergence between the 55% revenue growth and the modest 3% net profit growth highlights the capital-intensive nature of the recent expansion. While operational efficiency improved with EBITDA margins expanding to 33.81%, the integration costs and exceptional items dampened the bottom-line impact. The debt equity ratio stood at 0.82 times for the consolidated entity, reflecting the substantial leverage taken to fund the JB Pharma acquisition. However, the debt service coverage ratio remains healthy at 3.98 times, indicating sufficient cash flow to meet debt obligations despite the increased borrowings.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE685A01028/12cb5303f2504d2e.pdf